A5012173490- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Diagnosis and Treatment
- Estrogen and related hormone effects
- Breast Lesions and Carcinomas
- Economic and Financial Impacts of Cancer
- BRCA gene mutations in cancer
- Colorectal Cancer Treatments and Studies
- Immunotherapy and Immune Responses
- Neutropenia and Cancer Infections
- Brain Metastases and Treatment
- PARP inhibition in cancer therapy
- Ubiquitin and proteasome pathways
- Radiopharmaceutical Chemistry and Applications
- Protein Degradation and Inhibitors
- Lymphadenopathy Diagnosis and Analysis
- Cancer-related cognitive impairment studies
WinnMed
2014-2025
Mayo Clinic in Florida
2016-2025
Jacksonville College
2014-2025
Jacksonville University
2024
Nemours Children’s Clinic
2021-2024
Nemours Children's Clinic
2023-2024
St. George's University
2024
University of South Florida
2023
Mayo Clinic in Arizona
2022
Memorial Sloan Kettering Cancer Center
2022
Significant improvement in survival outcomes has been established with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2) -positive early breast cancer treatment. However, may increase risk cardiac toxicity, and long-term evaluation its incidence factors are warranted.NCCTG (Alliance) N9831 trial compared doxorubicin cyclophosphamide (AC) followed by either weekly paclitaxel (arm A); then B); or plus alone C) patients HER2-positive...
Abstract Outcomes have improved considerably in multiple myeloma (MM), but disparities among racial‐ethnic groups exist. Differences utilization of novel therapeutics are likely contributing factors. We explored such differences from the SEER‐Medicare database. A analysis lenalidomide, thalidomide, bortezomib, and stem cell transplant (SCT) was performed for patients diagnosed with MM between 2007 2009, including use over time, by race, time‐dependent trends each racial subgroup, survival...
pansion states.These findings are consistent with age-adjusted state cancer mortality data reported by the US Centers for Disease Control and Prevention, which do not clearly demonstrate a difference that favors either expansion or nonexpansion states (Figure 1). 4 Baseline between being same after adjusting predictors of outcomes known to differ from suggests similar care is offered in different states.Clinically meaningful baseline differences survival before Affordable Care Act, combined...
Summary Deubiquitinase enzymes ( DUB s) of the proteasomal 19S regulatory particle are emerging as important therapeutic targets in several malignancies. Here we demonstrate that inhibition two proteasome‐associated s USP 14 and UCHL 5) with small molecule inhibitor b‐ AP 15, results apoptosis human Waldenström macroglobulinaemia WM ) cell lines primary patient‐derived tumour cells. Importantly, 15 produced proteotoxic stress cells have acquired resistance to proteasome bortezomib. In silico...
BACKGROUND Outcomes have improved significantly in multiple myeloma (MM), but racial disparities health care access and survival exist. A comprehensive analysis exploring MM is warranted. METHODS Patients with from 1991 to 2010 the Surveillance, Epidemiology, End Results‐Medicare database were evaluated for trends clinical myeloma‐defining events (MDEs), receipt of treatment (drugs stem cell transplantation; [SCT]), cost care, overall (OS). RESULTS Among 35,842 patients, frequency all MDEs...
Abstract We conducted a surveillance epidemiology and end results ( SEER )‐based analysis to describe the incidence characteristics of second primary acute lymphoblastic leukemia sALL ) among adults (≥18 years) with history malignancies (1M). Standardized ratios SIR s) cases were calculated by site 1M stage. also evaluated differences in 5‐year survival age, site, extent 1M, latency after evidence underlying racial/ethnic disparity. identified 10,956 patients de‐novo/primary (1 ALL 772 ....
Background Invasive lobular carcinoma (ILC) comprises approximately ~10–20% of breast cancers. In general, multifocal/multicentric (MF/MC) cancer has been associated with an increased rate regional lymph node metastases. Tumor heterogeneity between foci represents a largely unstudied source genomic variation in those rare patients MF/MC ILC. Methods We characterized gene expression and copy number 2 or more from 11 ILC (all ER+, HER2-) adjacent normal tissue. RNA DNA were extracted 3x1.5mm...
The cost of cancer treatment is higher for breast than any other diagnosis, leaving women with metastatic vulnerable to challenges given the extended length treatment, including financial, physical, and psychological burdens. purpose this study was examine lived experiences diagnosed MBC in realm financial concerns unmet support needs specific their treatment. This qualitative, phenomenological included individual interviews that were audio-recorded transcribed verbatim. Applied thematic...
Context: Previous studies suggestthe effect of metformin on TSH levels, but its impacton free T4 (fT4) levels has not been understood clearly. Objective:This Meta-analysis aims to studythe effects serum-free T4(fT4) in patients with or without underlying thyroid disease and/or diabetes. Data Sources:We reviewed articles from the Cochrane Library based systematic protocol. Extraction: Demographic, clinical, and relevant data was extracted. were analyzed according changes fT4 administration....
Activation of the RAS/MAPK pathway is associated with reduced tumor-infiltrating lymphocytes and poor outcomes in triple-negative breast cancer (TNBC). Previous studies demonstrated that inhibition MAPK a MEK inhibitor synergistic immune checkpoint inhibitors. We conducted phase I/II trial pembrolizumab binimetinib patients metastatic TNBC ≤ 3 prior lines therapy. There were two dose levels (DL) at 45 mg DL 0 30 -1. The recommended II was standard twice daily. objective response rate (ORR)...
"QIM25-237: Supporting Oncologists in Capturing and Using Structured Oncology Data Real-Time the Electronic Health Record (EHR)" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Abstract Background: Endocrine therapy (ET) with aromatase inhibitors (AI) plus ovarian function suppression (OFS) is standard for premenopausal women ER+/HER2- breast cancer. However, many are intolerant of AI + OFS, leaving tamoxifen (with or without OFS) as their only option. Extensive studies have demonstrated that treated neoadjuvant ET whose tumors exhibit Ki-67 ≤ 10% following 4 weeks (defined endocrine sensitive disease (ESD)) achieve 5-year distant disease-free survival >...
<div>AbstractPurpose:<p>Activation of the RAS/MAPK pathway is associated with reduced tumor-infiltrating lymphocytes and poor outcomes in triple-negative breast cancer. Previous studies demonstrated that inhibition MAPK a MEK inhibitor synergistic immune checkpoint inhibitors.</p>Patients Methods:<p>We conducted phase I/II trial pembrolizumab binimetinib patients metastatic cancer ≤3 prior lines therapy. There were two dose levels (DL) at 45 mg DL 0 30...
1098 Background: Leucine-rich repeat-containing protein 15 ( LRRC15) has emerged as a potential biomarker and therapeutic target for various cancers due to its high expression in cancer-associated fibroblasts (CAFs) role tumor progression. High LRRC15 is associated with poor prognosis TNBC. This study aims define the multiomic profile of Methods: 3,038 TNBC samples were analyzed via Next-Generation Sequencing (592, NextSeq; Whole Exome Sequencing, NovaSeq) Transcriptome (NovaSeq; Caris Life...
1114 Background: While treatment and management of TNBC has improved, there is a need for novel prognostic biomarkers to better inform outcomes guide therapeutic options. ILF2 poorly characterized protein with pleiotropic functions that highly expressed in TNBC. Here we evaluated the associations 1) genomic transcriptomic data, 2) tumor microenvironment (TME), 3) clinical Methods: 15,544 breast cancer (BC) samples, including 3,038 TNBC, were tested by NGS (592, NextSeq; WES, NovaSeq) WTS...
TPS1125 Background: Despite the many available treatments for patients (pts) with HR+, HER2– recurrent/metastatic breast cancer (MBC), optimal treatment after progression on CDK4/6 inhibitors (CDK4/6i) is unclear. One possible CDK4/6i resistance mechanism increased expression of Aurora kinase A (AURKA), a key mitosis regulator associated poor prognosis. Further implicated in CDK 4/6i resistance, high c-Myc or RB1 loss function (LOF) are transcriptional co-regulation synthetic lethality,...
TPS2689 Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, existing FDA approved companion diagnostic biomarkers like PD-L1, dMMR/MSI-H and TMB low accuracy in predicting response. Ex vivo cytokine profiling of live tumor samples has shown promise as an improved means response to PD-1 blockade (Voabil, et al. Nat Med. 2021), but this approach been limited resections given the need for large amounts tissue. Here we present three clinical trials that...
National Cancer Institute (NCI)/National Comprehensive Network (NCCN)-designated cancer centers (CCs) offer patients state-of-the-art treatment, but their impact on multiple myeloma (MM) patient outcomes has not been evaluated.Adult MM diagnosed between 1973 and 2011 were identified from the Surveillance, Epidemiology, End Results database stratified by county of residence at time diagnosis year CC designation. The influence NCI/NCCN access, race, overall survival (OS) was evaluated with a...